MONALEESA-7Published on: 1 Jun 2019
ASCO 2019: Breast cancer - First proof of survival prolongation through CDK4/6 inhibition
The MONALEESA-7 trial shows that therapy with a CDK4/6 inhibitor, ribociclib, improves overall survival in combination with endocrine therapy. In addition, it demonstrates that CDK4/6 inhibition is equally effective in younger women.
